Neurocrine Biosciences Inc (NBIX) stock
NBIXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 19/307% below fair value
$162.86−3.06 (-1.84%)
Close on Nov 18, 2026Market cap $16.55BP/E 23.9Yield –
Neurocrine Biosciences pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Neurocrine Biosciences's pe ratio was 25.6× on Nov 11, 2026, against 36.4× a year earlier. Over the last 5 years it ranged from 17.3× to 959.3×, with a median of 42.4×.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 25.6× | −8.4 |
| 2025 | Dec 31, 2025 | 33.9× | −2.6 |
| 2024 | Dec 31, 2024 | 36.5× | −34.3 |
| 2023 | Dec 29, 2023 | 70.8× | −135.1 |
| 2022 | Dec 30, 2022 | 205.9× | +187.3 |
| 2021 | Dec 31, 2021 | 18.6× | −84.4 |
| 2020 | Dec 31, 2020 | 103.1× | −529.2 |
| 2019 | Dec 31, 2019 | 632.3× | +488.0 |
| 2013 | Apr 30, 2013 | 144.3× | +131.2 |
| 2012 | Oct 31, 2012 | 13.1× | +0.9 |
| 2011 | Dec 30, 2011 | 12.1× | – |
See a number that looks wrong?